<DOC>
	<DOC>NCT00002196</DOC>
	<brief_summary>The purpose of this study is to see if it is safe and effective to give CI-1012 to HIV-infected patients who do not have any symptoms of the disease. This study also examines how the body handles CI-1012.</brief_summary>
	<brief_title>A Study of CI-1012 in HIV-Infected Patients</brief_title>
	<detailed_description>Patients receive 2 weeks of oral CI-1012 therapy in this open-label study, with 8 patients entered at each dose level studied.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must have: Serologic evidence of infection with HIV1. CD4+ cell count &gt;= 200 cells/mm3. HIV1 RNA &gt;= 10,000 copies/ml. Exclusion Criteria Coexisting Condition: Patients with the following conditions are excluded: Viral, fungal, or bacterial infection requiring therapy other than topical medications. Concurrent Medication: Excluded: Prophylactic systematic antibacterial, antifungal or antiviral agents. Antiretroviral therapy. NOTE: Patient must be willing to remain off antiretroviral therapy for 1 week after completing study medication. Prior Medication: Excluded: Experimental therapy for &gt;= 4 weeks prior to initiation of study medication. Antiretroviral treatment for 3 weeks prior to initiation of study medication. Systemic steroids or anticancer agents for 4 weeks prior to initiation of study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>Dose-Response Relationship, Drug</keyword>
	<keyword>Administration, Oral</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>